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Treatment of diseases such as diabetes mellitus and cardiovascular disorders are highly dependent on medications and
particularly adherence to medications to achieve optimal pharmacotherapy outcomes. Several factors can affect a patient’s
adherence including: knowledge and beliefs about their illness and medications, concomitant psychological disorders, type
of therapeutic regimen, and lack of access to medicines. In Iran, a middle income country, essential medicines are highly
available and affordable. However, adherence to medications has not been emphasized especially for patients with diabetes
and cardiovascular diseases. In the present study, we reviewed the available literature on adherence to medications used to
treat diabetes and cardiovascular disorders in Iran. We systematically searched Scopus, Web of Science, PubMed, CINAHL,
Google Scholar, Scientific Information Database, and IranMedex using a highly sensitive protocol on July 2012. We retrieved
1003 citations; and two independent researchers screened them for relevant publications. Studies were included if they
reported rate or determinants of adherence to diabetes mellitus and cardiovascular medications. Trials on improving
interventions were also included. The quality of studies was assessed using appropriate guidelines. Fourteen studies were
eligible for data extraction and review. The definition of adherence and the measurement tools used were unclear among
studies. Methodological caveats including inappropriate sample size, sampling methods, inclusion/exclusion criteria, and
high rate of loss to follow-up were also observed. Nevertheless, adherence rate was reported to be 62.8-86.3% for oral
hypoglycemic medications and 38.8-60.0% for cardiovascular medicines. Forgetfulness, lack of knowledge about medical
condition and prescribed medications, and concerns about medications efficacy and side effects were consistently reported
as barriers to adherence. Patient education plus telephone or short message service follow-ups were reported to improve
adherence to oral hypo-glycemic medications. We did not find any high quality trials on adherence to cardiovascular
medicines. In conclusion, adherence to cardiovascular and diabetes medications is not assured in Iranian patients. Based on
the available literature, patient education and reinforcement interventions are required to address this issue. Future studies
should employ careful designs and standard tools for assessment of adherence to medications.
Keywords: Medication adherence, Patient compliance, Cardiovascular diseases, Hypertension, Diabetes mellitus,
Oral hypoglycemic medications, Patient education, IranIntroduction
Medicines play an important role in medical care; and ad-
herence to medications (AM) is essential to achieve best
possible pharmacotherapy outcomes [1,2]. Although there
is no consensus on the ideal rate of AM in medical litera-
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reproduction in any medium, provided the oradequate [3]. Some studies suggest that a limit of 95%
should be considered as an acceptable AM rate particu-
larly for certain medical conditions such as HIV/AIDS
[4,5]. Evidence shows that non-adherence to medications
results in higher health care costs, longer hospitalizations,
and increased morbidity and mortality [6-8].
Non-adherence to medications in patients with diabetes
mellitus (DM) and cardiovascular diseases (CVD) is of
major concern [9,10]. In Iran, prevalence of type 2 DM is
estimated to be 24% in adults aged over 40 years [11].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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estimated to be 2.04 billion US dollars [12]. In addition,
CVD is ranked as the third most important cause of dis-
ease and injury in the country [13]. Among CVD, hyper-
tension prevalence is estimated to be 17% while significant
rates of undiagnosed or uncontrolled cases have been re-
ported [14]. Unfortunately, AM has not been highlighted
for Iranian patients with DM or CVD and few studies have
focused on the rate and the determinants of adherence
[15,16].
Adherence to medications is a complex behavior which
can be influenced by patient, provider, and health system
factors [17]. Numerous factors including cognitive impair-
ments, adverse drug reactions, lack of knowledge about ill-
ness and pharmacotherapy regimen, complexity of the
regimen and poor access to medicines have been identified
to affect AM [18,19]. Several interventions including
reminder systems, follow-up programs by health care pro-
viders, and information technology tools have been devel-
oped to overcome patient and health care provider-related
barriers [20]. Nevertheless, addressing the health system
related factors such as access to medicines requires macro
level policy making particularly in resource-limited set-
tings [21]. In contrast to many other developing countries,
access to medicines in Iran is reported to be addressed ad-
equately through local production of generic medicines
[22]. However, achieving optimal clinical outcomes re-
quires patients’ adherence with the therapeutic regimen.
In the present study, we performed a comprehensive
and systematic review of the available literature to identify
the rate and the determinants of adherence to DM and
CVD medications in Iran. We also reviewed publications
on adherence to medications improving interventions in
patients with DM and CVD.
Methods
We searched international biomedical databases including
Scopus, Web of Science, PubMed, CINAHL, and Google
Scholar. National electronic databases including Scientific
Information Database (SID) and IranMedex were also
searched for Farsi or English language publications.
Search strategy
We used MeSH terms “Medication Adherence” or “Patient
Compliance” and other text words to develop our search
protocol. Text words related to medicines included “medi-
cation, medicines, drug, therapy, treatment, and regimen”
and keywords related to AM were “compliance, adherence,
compliant, adherent, nonadherence, noncompliance, non-
adherent, and noncompliant”. We used “Iran or Iranian” to
restrict our search in international databases to publica-
tions related to Iran. National databases were searched
using English keywords and their Farsi equivalent terms.
To reach maximum sensitivity in our search protocol, wedid not restrict for disease type. No restrictions were set for
either time or type of publications. All database searches
were carried out on July 2012.
Study selection
All records retrieved from international databases were
imported into a bibliographic software (EndNote® X5) li-
brary. Two independent researchers screened title and
abstract of each record to find relevant publications and
disagreements were resolved by discussion. Records in
national databases were screened online as no export
option was available for bibliographic software.
All articles which had reported the rate or score of ad-
herence to DM or CVD medications in Iran were in-
cluded in the study. Studies which had focused on AM
determinants or AM improving interventions were also
included. Studies were excluded if AM was reported as
part of a clinical trial since patients were intended to
have acceptable AM in such studies. After the screening
phase, the full-text of relevant articles was retrieved if
available online or through contact with corresponding
authors. We contacted all the corresponding authors to
ask for any unpublished data or any publications not re-
trieved during the bibliographic search.
Data extraction and analysis
Two independent teams of researchers reviewed the full-
text articles according to the inclusion–exclusion criteria.
If articles were eligible for the study, reviewers extracted
data on study characteristics and outcomes using a stan-
dardized extraction chart. Specific information on study
design (randomized controlled trial, cohort, cross-sectional,
qualitative), study setting, AM definition and rate, AM
measurement tool (self-report, pill count, refill data, elec-
tronic medication monitors, or biological assessments), and
AM determinants were recorded. Disagreements were re-
solved by discussion. Quality assessment was performed
using an adapted version of STROBE checklist for cross
sectional studies and CASP tools for clinical trials and
qualitative studies (each of the checklists consisted of ten
items-10 points) [23,24]. Studies were categorized as low
(0–3 points), moderate (3–7 points) and high (7–10 points)
quality by two independent teams of researchers and dis-
agreements were resolved by discussion. The low quality
studies were excluded and data were extracted from moder-
ate and high quality studies. We did not employ a meta-
analysis approach as AM definitions and measurement
tools were highly diverse among studies.
Results
Overview
Our study retrieved 1003 citations of which 14 were eli-
gible for data extraction and review (Figure 1). Of 14
publications, six articles were related to DM and eight
Figure 1 Flow diagram of study selection. n1: number of records in
international database, n2: number of records in national database.
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were in Farsi language and were retrieved from national
databases. Adherence to medications was the primary
objective in eight studies. A majority of publications
were reports of cross-sectional studies (8 articles). A
summary of studies is provided in Tables 1 and 2.
Adherence definition
The definition of adherence was highly diverse and un-
clear among studies. Four studies had operationalized
adherence definition as “percent of medications consump-
tion” [15,16,25,26]. They had categorized adherence rate
as good, fair, or poor; but the cut off thresholds were not
exactly comparable. Four studies had used “adherence
score” which was calculated on the basis of self-report
questionnaires [27-30].
Adherence measurement tools
Self-report approach was employed in 11 quantitative stud-
ies; however, different measurement tools were used. Three
studies had utilized translated versions of standard AM as-
sessment questionnaires including “Morisky Medication
Adherence Scale (MMAS)” and “Medication Adherence
Rating Scale (MARS)” [30-32]. In other studies, question-
naires were developed according to the study objectives.
Few studies used pill count technique [15,25,26].Summary of studies
Diabetes mellitus
Three studies investigated the effects of demographic fac-
tors, knowledge of disease and belief about medications
on adherence to oral hypoglycemic agents [15,26,31]. Self-
reported causes for non-adherence to medications were
reported in two of the studies (Table 3) [15,26]. One study
showed that adherent patients achieved an improved clin-
ical outcome (HbA1c) in comparison with their non-
adherent counterparts (7.1% ±1.2% vs. 7.8% ±1.3% for
metformin users and 7.2% ±1.2% vs. 7.9% ±1.4% for gly-
buride users, respectively) [21]. Adherence to insulin ther-
apy was investigated in one qualitative study [33]. Findings
revealed five categories of AM determinants: (1) fear of in-
sulin injection due to pain and blood (2) disturbance of
daily life (3) negative attitudes about insulin side effects
and its stigmatization (4) lack of proper training (5) im-
paired physical and financial competence.
Few studies had evaluated interventions to improve AM in
Iranian diabetic patients. Two studies evaluated nurse-led in-
terventions using telephone or cell phone text messages fol-
lowing diabetes training workshops [27,28]. Telephone
follow-up consisted of 16 phone calls and the text message
intervention utilized 72 messages during 3 months. Both
studies revealed significant improvements of AM scores in
the intervention groups comparing to usual care.
Cardiovascular diseases
Three studies had evaluated the determinants of adher-
ence to medications in cardiovascular diseases (Table 4)
[16,25,32]. Another study evaluated the relationship be-
tween a psychological model and adherence to hyperten-
sion therapeutic regimen (diet, exercise, and medications).
Although, a distinct score was reported for AM, the deter-
minants of adherence were analyzed for the therapeutic
regimen as a whole [29]. A grounded theory-based study
described the deficiencies of hypertension care (including
medications) for Iranian patients [34]. The study suggested
a “Partnership Care Model” in which non-adherence was
in a reciprocal relationship with lack of knowledge and
lack of effective care. One study reported that patients
who were adherent to their medications had significantly
lower systolic and diastolic blood pressures (mean differ-
ence: 10.2 and 5.1 mmHg, respectively) [16]. In another
study, non-adherence or non-persistence to medications
were identified as a main cause of rehospitalization (23%
of cases) for CVD patients [35].
We found no high quality trials on AM improving
intervention for CVD patients. However, two studies re-
ported the effect of training and follow-up interventions
for hypertensive patients [30,36]. Hadi et al. reported
that face to face training plus educational booklet alone,
weekly telephone follow-up, or weekly telephone follow-
up and educational booklet are all effective strategies in
Table 1 Summary of studies on adherence to diabetes medications
Author/
language
(En/Fa)a
Publication
year
Study
design
Study population/
location
Sample
size
Study aim/type
of intervention
Adherence definition Adherence
measurement
tool
Adherence
rate/score
Study
qualityc
Aflakseir31
(En)
2012 Cross-
sectional
Type 2 diabetes
An outpatient clinic
Shiraz
102 To examine the role of illness and
medication perceptions on
medication adherence in a group
of Iranian patients with type 2
diabetes
“The score higher than
midpoint has been
considered as the index of
adherence”
Self-report
questionnaire
(MARSb)
Adherence rate: 87% ***
Zolfaghari
et al. 27
(En)
2011 Quasi-
experimental
(Randomized
trial)
Type 2 diabetes
Iranian Diabetes
Association
Tehran
77 Three-day live education plus: Not Defined Self-report
questionnaire/
11 items
Pre-test/Post-test
scores (max. 100):
SMS: 73.27/94.73
Telephone:
75.48/91.13
***
1. Short message service (SMS)
2. Telephone follow-up by nurse
Alizad
et al. 33 (Fa)
2011 Qualitative Insulin dependent diabetic
patients (type 1 & 2)
64 To investigate the determinants of
non-adherence to insulin therapy
in type 1 and 2 diabetic patients
Not Defined Not Defined Not Applicable ***
Medical University-
affiliated DM centers of
Tehran, Tabriz, Rasht, and
Mashhad
Farsai
et al. 15
(En)
2011 Cross-
sectional
Type 2 diabetes
Research Center
Clinic
Isfahan
248 To determine the adherence to
oral hypoglycemic medications
and associated factors
“Patients who take 90-105%
of medications are consid-
ered as adherent”
Self-report
questionnaire/
Pill count
Adherence rate:
62.3%/62.8%
**
Nesari
et al. 28
(En)
2010 Randomized
controlled
trial
Type 2 diabetes
Iranian Diabetes
Association
Tehran
61 Three-day live education plus: Not Defined Self-report
questionnaire/
7 items
Pre-test/Post-test
scores(max. 100):
Intervention: 61.11/
89.55
***
1-Telephone follow-up by nurse
2- Usual care
Control: 75.66/78.00
Dabaghian
et al. 26 (Fa)
2005 Cross-
sectional
Type 2 diabetes
Two tertiary
hospitals
Tehran
256 To determine the medication
adherence rate and its association
with patients knowledge and
attitude about diabetes care
Compliance=[(N-n)/N]*100
N: Number of prescribed
medications
Pill count Adherence rate: **
Good: 86.3%
Fair: 7%
Bad: 6.6%n: Number of consumed
medications
C > 90% : Good
80 < C < 90 : Fair
C < 80 : Bad
aEn: English, Fa: Farsi, bMedication adherence reporting scale, cQuality rating: *Low, **Moderate, ***High.
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Table 2 Summary of studies on adherence to cardiovascular medications
Author/
language
(En/Fa)a
Publication
year
Study design Study population/
location
Sample
size
Study aim/type
of intervention
Adherence
definition
herence
asurement tool
Adherence
rate/score
Study
qualitye
Heydari et al. 29
(En)
2011 Cross-
sectional
Heart Failure 108 To investigate the
relationship of a
psychological model with
adherence to therapeutic
regimen
Not Defined f-report
estionnaire/4 items
Adherence
score 56.9
(max. 100)
***
Two tertiary hospitals
Mashhad
Heydari et al. 35
(Fa)
2011 Cross-
sectional
CVDb 600 To determine the
frequency of
rehospitalization and
its contributing
factors
“Stop drug intake
or irregular intake
in second admission
group”
f-report
estionnaire/6 items
Not
Applicable
***
Five hospitals
Mashhad
Mohammadi
et al. 36 (Fa)
2006 Randomized
controlled trial
Hypertension
One hospital
Ardabil
200 Face to face education
and a follow-up program
using home visits for
3 months
“Regular intake of
medications”
t Defined Adherence
rates:
**
Pre-test/
Post-test:
Control group:
35.87%/42.4%
Intervention
group 39.13%/
44.6%
Hadi et al. 30
(En)
2006 Randomized
controlled trial
Hypertension
Outpatient Clinic
Shiraz
150 A four-arm trial, Live
training plus one of the
following reinforcement
methods: (1) Telephone
follow-up (2) Telephone
follow-up plus educational
booklet (3) educational
booklet only (4)Usual care
Adherence score was
calculated. (range: 0–5)
f-report
estionnaire/5 items
odified MMASd)
Adherence
score :
**
Pre-test/
Post-test
(1) 2.67/4.14
(2) 2.25/3.88
(3) 2.82/4.35
(4) 2.92/4.23
Abbasi
et al. 32 (Fa)
2005 Cross-
sectional
Hypertension
Tehran Heart
Center Clinic
Tehran
380 Identification of compliance
rate to drug regimens and
its association with patients’
health beliefs
Adherence: f-report
estionnaire
MAS)
Adherence rate:
60%
**
0-1 : Good
2-4 : Poor
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Table 2 Summary of studies on adherence to cardiovascular medications (Continued)
Hadi et al. 16
(En)
2004 Cross-
sectional
Hypertension 250 To investigated factors
associated with medication
compliance among hypertensive
patients
“proportion of amount
of drugs used by patients
compared to the amount
of drugs, which had been
prescribed” >90% = good
compliance
Self-report
questionnaire
Adherence rate:
39.6%
***
Outpatient Clinic
Shiraz
Parsa-Yekta
et al. 25 (Fa)
2004 Cross-
sectional
CADc
Outpatient clinic
Tehran
150 To identify factors related
to medication compliance
“percent of taken tablets”
Good: 95-100%
Moderate: 90-95%
Weak: 56%
Pill count Adherence rate: ***
Pill count:
Good: 28%
Weak: 56%
Mohammadi
et al. 34 (En)
2002 Qualitative
(Grounded
Theory)
Hypertension 12 To identify the conceptual
structure of high blood
pressure control in an
Iranian hypertensive population
(to develop a theoretical
explanation for the issue)
Not Defined Not Applicable Not Applicable ***
Patients, Physicians,
and Nurses were
interviewed
Location unclear
aEn: English, Fa: Farsi, bCardiovascular diseases: heart failure, ischemic heart disease, cardiac arrhythmia, deep vein thrombosis, cardiac valve diseases. cCoronary artery disease: myocardial infarction, angina pectoris.
dMorisky medication adherence scale, eQuality rating: *Low, **Moderate, ***High.
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Table 3 Determinants of adherence and self-reported
causes of non-adherence to diabetes medications
Determinants of adherence
Factor Effect
Age (−); r= −0.2 [31]
(+); >45 years, p<0.001 [26]
(×)[15]
Gender (×) [15,26]
Education level (×) [26,31]
(+); p=0.007 [15]
Duration of pharmacotherapy (×); [15,26,31]
Beliefs about medications (−); r= −0.44 (concerns) [31]
(+); p=0.009 (positive attitude) [26]
Knowledge of the disease (+); p=0.01 [26]
Self-reported causes for non-adherence
Cause Frequency
Forgetfulness 38% [15]
27% [26]
Medications not available 15.2% [26]
Regimen Complexity 15.1% [15]
Fasting during Ramadan 11% [15]
Feeling well/Lack of symptoms 7% [26]
(+) shows a direct/positive association or correlation (−) shows an inverse/
negative association or correlation, (×) shows no significant relationship.
Table 4 Determinants of adherence and self-reported
causes of non-adherence to cardiovascular medications
Determinants of adherence
Factor Effect
Age (+); >50 years, p= 0.01 [16]
(−); p<0.005 [25]
Education level (+); p<0.005 [25]
Insurance coverage (+); p= 0.01 [16]
(×) [25]
Employment (+); p< 0.005 [25]
Duration of pharmacotherapy (+); <1 year, p= 0.002 [16]
(−); p<0.005 [26]
Number of medications (×); p= 0.78 [16]
Beliefs about medications (+); p=0.006 [16]
(×); [25]
Perception of disease severity (+); p= 0.01 [32]
Perception of barriers to medications
use
(+); p< 0.001 [32]
Knowledge of disease (+); p= 0.01 [6]
of medications (+); p< 0.005
[25]
Regular visits with physician (+); p=0.001 [16]
Self-reported causes for non-adherence
Cause Frequency
Forgetfulness 30.1% [25]
Lack of symptoms 20.4% [25]
Side effects 15.6% [25]
Lack of efficacy 9.6% [25]
(+) shows a direct/positive association or correlation (−) shows an inverse/
negative association or correlation, (×) shows no significant relationship.
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was observed between study groups (61% loss to follow-
up) [30]. In contrast, Mohammadi et al. evaluated the
impact of a program consisted of face to face training
session at clinic and monthly home visits. The authors
reported that the program was not significantly success-
ful in comparison with the control group. However, am-
biguity exists in the definition of AM and outcome
assessment tool of the study [36].
Discussion
In the present review, we encountered a range of studies
regarding AM definition, measurement tools, and method
of reporting (rate vs. score). Nevertheless, some studies
have reported adherence rates of 62.3% to 87% among dia-
betic patients and 28% to 60.0% among patients with CVD
in Iran [15,25,31,32]. These findings are comparable with
international literature reports of AM rates to be 50-70%
for various medical conditions [2,9,21]. Despite methodo-
logical issues which will be discussed later in this section,
insufficient rate of AM is evident for both DM and CVD
medications in Iran. Moreover, we found two studies which
reported the association of clinical outcomes (lower HbA1c
and blood pressure levels) with higher adherence rate to
DM and CVD medications in Iranian patients [15,32].
Such findings are also in line with other studies which haverevealed the association of AM with improved clinical out-
comes and lower morbidity and mortality rates [37-40].
Patient-related factors including demographic character-
istics, knowledge and beliefs about illness and medications,
concomitant psychological disorders, and therapeutic regi-
men characteristics have been mostly linked to nonadher-
ence behavior [18,40,41]. In Iranian patients, factors such
as age, education level, duration of pharmacotherapy, and
insurance coverage did not influence AM consistently ( i.e.
positive, negative or neutral associations have been re-
ported) [15,16,25,26,31,32]. In contrast, patients’ know-
ledge of their illness or medications and their beliefs about
medications efficacy or side effects were reported to ad-
versely affect AM in all studies [16,25,26,31,32]. Forgetful-
ness, lack of symptoms, fasting during Ramadan, lack of
efficacy, and fear of side effects were among self-reported
causes of non-adherence to medications [15,25,26]. Quan-
titative studies as well as qualitative studies have docu-
mented the importance of appropriate knowledge of and
positive attitudes toward medications effect [33,34]. Based
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priate knowledge and negative attitudes is the most im-
portant barrier to adherence for patients with DM and
CVD. Patient education programs are required to ensure
optimal adherence rates. Patients reported forgetfulness as
the most frequent cause of non-adherence. Forgetfulness
could be addressed by modification of dosing schedules
based on patients’ daily routines and also the use of re-
minder systems such as programmed devices, special re-
minder pill packaging, and appointment/prescription refill
reminders [20,42-44].
We found few studies on interventions to improve
AM in Iranian patients. In two studies, patient education
plus telephone or short message follow-up services were
evaluated for diabetic patients. Education alone was not
able to improve AM but education plus any of the
follow-up tools could significantly improve adherence
and clinical outcomes [27,28]. This is in line with the re-
sults of a recent systematic review concluding that pa-
tient education alone does not seem to be successful in
improving AM in hypertensive patients [45]. Thus, pa-
tient education must be accompanied by continuous
support and reinforcement to maximize the effect of in-
terventions. Tele-communication technologies including
different telephone and cell phone services can be uti-
lized as valuable support tools.
Implications for research
The definition of AM and the terminology used for various
aspects of non-adherence are highly diverse in the litera-
ture. This weakness is also observed among Iranian publi-
cations. However, international initiatives have focused on
standardizing concepts of AM research [1,46,47] and future
studies are encouraged to comply with these research
guidelines. There are different methods of measuring AM
including pill count, pharmacological and biochemical
markers, medical and dispensing records, self-report, and
Medication Event Monitoring System (MEMS) [2]. In our
review, almost all studies had used self-report or pill count
method to measure AM. In Iran, DM and CVD medica-
tions can be obtained from pharmacies without restrictions.
Such access to medicines may deteriorate the validity of pill
count method. In addition, unstandardized self-report
questionnaires neither guarantee the accuracy of AM meas-
urement nor can assure the generalizability of the results
among studies. However, lack of prescription refill databases
and high cost of MEMS devices limit their application for
AM research and clinical practice. We believe that self-
report method may be considered as the most appropriate
tool for measuring AM in clinical practice and research in
Iran. Standardized self-report questionnaires such as Morisky
Medication Adherence Scale and Hill-Bone Compliance
Scale shall be adapted and validated for Iranian patients
[48]. We also observed various methodological weaknessesincluding lack of sample size calculation, non-probability
sampling method, small sample size, and undefined inclusion
criteria in Iranian studies. Such limitations should be taken
care of in future studies in order to guarantee the internal
and external validity of the results.
Conclusion
Although medicines are highly accessible in Iran, patient-
related factors in particular, lack of knowledge and positive
attitudes about the illness and medications have resulted in
impaired adherence with DM and CVD medications. We
strongly suggest that health care professionals consider pa-
tients’ non-adherence to medications as a principal under-
lying factor for non-improvement in clinical outcomes.
Furthermore, health policy makers should consider impaired
AM as a major issue which requires multidisciplinary pol-
icies and interventions involving clinicians and other health
professionals including pharmacists and nurses to be ad-
dressed the issue. Based on the available evidence, interven-
tions should focus on patient education and reinforcement.
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